VAXCYTE, INC. Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period
VAXCYTE, INC. (PCVX) reported Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period of 824.08 thousand shares for the 9-month period ending 2024-09-30, per its 10-Q filed 2024-11-05.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod · last filed 2024-11-05
- VAXCYTE, INC. share-based compensation arrangement by share-based payment award, equity instruments other than options, grants in period for the quarter ending 2024-09-30 was 123.53K shares, a 124.48% increase year-over-year.
- VAXCYTE, INC. share-based compensation arrangement by share-based payment award, equity instruments other than options, grants in period for the quarter ending 2024-06-30 was 134.87K shares, a 88.71% increase year-over-year.
- VAXCYTE, INC. share-based compensation arrangement by share-based payment award, equity instruments other than options, grants in period for the quarter ending 2024-03-31 was 565.68K shares, a 51.07% increase year-over-year.
- VAXCYTE, INC. share-based compensation arrangement by share-based payment award, equity instruments other than options, grants in period for the quarter ending 2023-12-31 was 73.17K shares, a 35.10% increase year-over-year.
- VAXCYTE, INC. share-based compensation arrangement by share-based payment award, equity instruments other than options, grants in period for fiscal 2023 was 574.12K shares, a 1.19% decline from fiscal 2022.
- VAXCYTE, INC. share-based compensation arrangement by share-based payment award, equity instruments other than options, grants in period for fiscal 2022 was 581.05K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period 12 month |
|---|---|---|---|---|
| 2024-09-30 | 123.53K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-05 | 258.39K shares derived: sum of 2 quarters · filed 2024-11-05 | 824.08K shares 10-Q · filed 2024-11-05 | 897.25K shares derived: sum of 4 quarters · filed 2024-11-05 |
| 2024-06-30 | 134.87K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | 700.55K shares 10-Q · filed 2024-08-06 | 773.72K shares derived: sum of 3 quarters · filed 2024-08-06 | 828.75K shares derived: sum of 4 quarters · filed 2024-08-06 |
| 2024-03-31 | 565.68K shares 10-Q · filed 2024-05-08 | 638.85K shares derived: sum of 2 quarters · filed 2024-05-08 | 693.88K shares derived: sum of 3 quarters · filed 2024-05-08 | 765.35K shares derived: sum of 4 quarters · filed 2024-05-08 |
| 2023-12-31 | 73.17K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | 128.20K shares derived: sum of 2 quarters · filed 2024-02-27 | 199.66K shares derived: sum of 3 quarters · filed 2024-02-27 | 574.12K shares 10-K · filed 2024-02-27 |
| 2023-09-30 | 55.03K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-06 | 126.50K shares derived: sum of 2 quarters · filed 2023-11-06 | 500.95K shares 10-Q · filed 2023-11-06 | 555.11K shares derived: sum of 4 quarters · filed 2024-02-27 |
| 2023-06-30 | 71.47K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | 445.92K shares 10-Q · filed 2023-08-08 | 500.08K shares derived: sum of 3 quarters · filed 2024-02-27 | 577.32K shares derived: sum of 4 quarters · filed 2024-02-27 |
| 2023-03-31 | 374.46K shares 10-Q · filed 2023-05-08 | 428.62K shares derived: sum of 2 quarters · filed 2024-02-27 | 505.86K shares derived: sum of 3 quarters · filed 2024-02-27 | 581.68K shares derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-12-31 | 54.16K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | 131.40K shares derived: sum of 2 quarters · filed 2024-02-27 | 207.22K shares derived: sum of 3 quarters · filed 2024-02-27 | 581.05K shares 10-K · filed 2024-02-27 |
| 2022-09-30 | 77.24K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-07 | 153.06K shares derived: sum of 2 quarters · filed 2022-11-07 | 526.89K shares 10-Q · filed 2022-11-07 | |
| 2022-06-30 | 75.83K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | 449.65K shares 10-Q · filed 2022-08-08 | ||
| 2022-03-31 | 373.82K shares 10-Q · filed 2022-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 |